New combo shows promise for rare, aggressive cancer
NCT ID NCT02820857
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 24 times
Summary
This study tested whether adding bevacizumab to standard chemotherapy (Folfiri) helps people with advanced neuroendocrine carcinoma live longer after their first treatment stops working. The trial included 153 adults with aggressive, inoperable cancer. The main goal was to see how many patients were still alive 6 months after starting the new combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Département d'Oncologie Médicale, Hôpital Saint-Antoine
Paris, 75012, France
-
Département d'Oncologie Médicale, Institut Paoli Calmettes
Marseille, 13009, France
-
Département de Cancérologie Urologique et Digestive, Centre Oscar Lambret
Lille, 59020, France
-
Département de cancérologie médicale - Groupe des tumeurs endocrines, Centre Léon Bérard
Lyon, 69008, France
-
Pôle Régional de Cancérologie, CHU de Poitiers
Poitiers, 86021, France
-
Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Européen Georges Pompidou, APHP
Paris, 75015, France
-
Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Sud, CHU d'Amiens
Amiens, 80054, France
-
Service d'Hépato-Gastroentérologie et Cancérologie, Hôpital Robert Debré, CHU de Reims
Reims, 51100, France
-
Service d'Hépato-Gastroentérologie et Oncologie Digestive, CHU de Dijon
Dijon, 21000, France
-
Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital Haut Lévêque, CHU Bordeaux
Pessac, 33604, France
-
Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital de la Timone, APHM
Marseille, 13365, France
-
Service d'Hépatogastroentéologie, Hôpital Michallon, CHU de Grenoble
Grenoble, 38043, France
-
Service d'Hépatogastroentérologie, CHR d'Orléans
Orléans, 45067, France
-
Service d'Hépatogastroentérologie, CHU d'Angers
Angers, 49933, France
-
Service d'Hépatogastroentérologie, Hôpital Pontchaillou, CHU de Rennes
Rennes, 35000, France
-
Service d'Oncologie Endocrinienne, Institut Gustave Roussy
Villejuif, 94805, France
-
Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, 69437, France
-
Service d'Oncologie Médicale, Hôpital Civil, CHU de Strasbourg
Strasbourg, 67200, France
-
Service d'Oncologie Médicale, Hôpital Saint Eloi, CHU de Montpellier
Montpellier, 34298, France
-
Service d'Oncologie et Radiothérapie, Institut Sainte Catherine
Avignon, 84918, France
-
Service de Gastro-Entérologie, Hôpital Nord, CHU de ST-Etienne
Saint-Priest-en-Jarez, 42270, France
-
Service de Gastroentérologie et Oncologie Digestive, Hôpital Avicenne
Bobigny, 93000, France
-
Service de Gastroentérologie et Pancréatologie, Hôpital Beaujon, APHP
Clichy, 92118, France
-
Service de Gastroentérologie, CHU Henri Mondor
Créteil, 94000, France
-
Service de Gastroentérologie, CHU de Rouen
Rouen, 76031, France
-
Service de Gastroentérologie, Hôpital Cochin, APHP
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.